APP and Alzheimer disease: GSK-3β phosphorylates PS1 at serine residues (Ser353 and Ser357), restraining APP cleavage and Aβ production while modulating the Aβ 42/40 ratio, thereby exacerbating AD (Maesako et al., 2011).